BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...
Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.
Becton Dickinson's (NYSE:BDX) stock is up by 4.3% over the past month. As most would know, long-term fundamentals ...
Becton Dickinson and Co (BDX) stock saw a modest uptick, ending the day at $237.38 which represents a slight increase of $1.08 or 0.46% from the prior close of $236.3. The stock opened at $236.51 and ...
BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...
Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of ...
Below is Validea's guru fundamental report for BECTON DICKINSON AND CO (BDX). Of the 22 guru strategies we follow, BDX rates highest using our P/E/Growth Investor model based on the published ...
In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...
Charting, Price Performance, News & Related Contracts.